FDA Accepts Supplement Application for YERVOY (ipilimumab)
The FDA has accepted a supplemental application for YERVOY, an immune checkpoint inhibitor.
Therapeutic Area
Therapeutic area intelligence for Immune Checkpoint Inhibitor with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.